Combination Therapy for Cyclic Vomiting Syndrome

"As per the guidelines listed for this trial, individuals aged 18 to 65 are eligible for enrollment."

"Presently, there are 9 clinical trials in progress related to haloperidol. Of these studies, 3 have progressed into Phase 3 and are being conducted at 51 locations centered around Saint Joseph, Michigan."

"This trial is primarily tracking how well the treatment works to reduce nausea at two, twenty-four and forty-eight hours. Secondary endpoints of interest include the proportion of patients who are issued discharge orders in 2 hours, differences in abdominal pain scores relative to baseline at 1,2 24 and 48 hours, as well as assessing when rescue narcotics become necessary within the emergency department."

"Haloperidol is often employed to assuage nausea, as well as address agitation, hyperactivity and hostile reactions."

"Yes, the listings on clinicaltrials.gov confirm that this medical trial is recruiting participants as of October 25th 2022. It was initially posted August 30th 2021 and seeks to enrol 100 subjects across a single location."

"Haloperidol's safety is rated a 2 on the scale, as there exists some evidence of its security but no proof for effectiveness in this Phase 2 trial."

"To be eligible for this research, individuals must have experienced vomiting and lie within the age group of 18 - 65. The trial is seeking to enrol approximately one hundred participants in total."

"According to clinicaltrials.gov, the recruitment of patients for this medical trial is still ongoing since it was first made available on August 30th 2021 and updated lastly in October 25th 2022."